Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust ...

("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in ...

Maximal level of SRC inhibition in patient samples after a single dose of NXP900 exceeded 90%. Three preclinical posters highlight ... ,“This year's AACR presentations mark an important ...

Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the publication of 3 abstracts for poster presentations at the ...

Researchers are just beginning to understand how microplastics might be affecting human health. A Reporter visited a lab to ...

Canva Code is one of the newest features Canva is rolling out and I have to say, I find it genuinely helpful. With Canva Code ...

Patients with advanced chronic kidney disease are at increased risk of hemorrhagic peptic ulcer disease hospitalization and adverse outcomes.

According to Future Market Insights, myelofibrosis (mf) treatment market is expected to grow at a CAGR of 5.5% between 2023 and 2033, reaching USD 1,280 Million by 2033. The market is expected to ...

Additionally, Zymeworks scientists co-authored two poster presentations focused on leveraging technologies ... a robust and ...

Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission ...